* Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected
to report resultson February 8 (estimated) for the period ending
December 31 2023
* The Cranford New Jersey-based company is expected to
report
revenue of $21.295 million, according to the mean estimate from
2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Citius Pharmaceuticals
Inc is
for earnings of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4.00, above its last closing price
of $0.60.
This summary was machine generated February 6 at 11:04 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)